Skip to main content

Table 1 Baseline characteristic of patients

From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

Age-yr
 Median 60
 Range 21–81
Sex-no. (%)
 Male 39 (56,5)
 Female 30 (43,5)
ECOG performance status- no.(%)
 0 20 (29)
 1 37 (53)
 2 12 (18)
Site of primitive melanoma- no.(%)
 skin 58 (84)
 uveal 3 (4)
 mucosal 2 (3)
 unknown 6 (9)
Melanoma stage-no.(%)
 M1a 5 (8)
 M1b 13 (18)
 M1c 51 (74)
Site of metastases-no.(%)
 1 16 (25)
 2 19 (27)
  ≥ 3 34 (48)
Brain metastases-no.(%)
 yes 10 (15)
 no 59 (85)
BRAF status-no. (%)
 Wild type 31 (46)
 BRAF V600 7 (13)
 BRAF not V600 3 (2)
 Unknown 28 (41)
Prior adjuvant therapy no.(%)
 vaccine 2 (3)
 interferon 13 (19)
 none 54 (47)
Disease free survival-months
 Median 13
 Range 0–136
Basal level of LDH (normal range 240–480 mg/dl)
 High 29 (42)
 Normal 40 (58)